NCT05949944

Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma

Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma：a Single-Arm, Open Lable， Multicenter Clinical Trial（LINCH Study）

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This phase Ib/II, single arm, open label, multicenter study is conducted to evaluate the efficacy and safety of linperlisib in combination with CHOP for newly diagnosed PTCL patients, and explore the reasonable dosage of linperlisib when combined with CHOP regimen.

Conditions

• Peripheral T-cell Lymphoma

Interventions

Type	Name	Description
DRUG	Linperlisib in combination with CHOP	Patients will receive six cycles of induction therapy of linperlisib in combination with CHOP regimen. All patients with CR and PR after induction therapy receive linperlisib maintenance therapy every 28 days until disease progression or other reasons lead to discontinuation, and the duration of linperlisib maintenance does not exceed 24 months.

Timeline

• Start date: 2023-08-15
• Primary completion: 2026-08-01
• Completion: 2026-12-01
• First posted: 2023-07-18
• Last updated: 2024-05-17

Locations

1 site across 1 country: China